NextGen Sciences Inc. has launched its first multiple protein (multiplex) assay, plasmadiscovery41, for oncology biomarker discovery and qualification. The assay simultaneously measures 41 human plasma proteins that are thought to have potential as biomarkers in cancer, particularly breast, prostate and lung cancers.

Sigma Life Science has announced the addition of 1,400 new European Collection of Cell Culture (ECACC) cell lines to its collection of cell line cultures and services.

New U.S. patent adds to four others received over last six months.

Targeted antibody bavituximab to be evaluated in combination with pemetrexed and carboplatin for front-line non-small cell lung cancer.

The project is designed to further validate the efficiency of Onko-Sure® relative to the CEA marker in colorectal cancer patients.

MDV3100 continues to show durable antitumor activity as evaluated by median times to prostate-specific antigen progression and radiographic progression.

Research published in molecular therapy shows gene specific silencing resulted in up to a 60-fold decrease in tumor volume.

LungExpress Dx™ is a proprietary gene expression-based test to improve upon staging for identifying those patients with early-stage NSCLC.

Data support clinical studies in bone cancer planned for 2011.

Company receives CTA approval to conduct two Phase III clinical studies of picoplatin, in the treatment of second-line SCLC and second-line ovarian cancer in the People's Republic of China.